NEWU Enables Path to Positive ROI for Payers,
Employers, and Value-Based Providers Burdened by Soaring Health
Costs and GLP-1 'Sticker Shock'
TORONTO, Jan. 29,
2024 /CNW/ - Newtopia Inc. ("Newtopia" or the
"Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled
whole health platform for creating habits that prevent, slow and
reverse chronic disease, today announced GLP-1 Sustain, a
companion program to specifically support and extend the dramatic
clinical outcomes produced by glucagon-like-peptide-1 (GLP-1)
receptor agonists and other related agonist drugs at a critical
juncture in the patient journey - once a user first encounters a
"weight loss plateau"i and even if users cease
taking the medication entirely.
In so doing, Newtopia's GLP-1 Sustain brings to market a
much-needed pathway to ensure that the many short-term health
benefits of these medications may be long-lasting and that the
significant costs to invest in them may in fact yield a
positive ROI for payers, employers, value-based providers, and
patients.
Newtopia's habit change platform is already proven for its
unrivaled ability to generate and maintain high levels of
user-engagement for periods of two years and beyond. Newtopia leads
the industry by consistently demonstrating 70% of its participants
as actively engaged at 12 months, and over 60% engaged at 24
months.ii
Through its unique engagement capabilities, Newtopia cultivates
positive lifestyle habits among its participants focused on
nutrition, exercise, and emotional well-being. According to
published results of a randomized controlled clinical trial (RCT)
on 2,835 individuals with increased waist circumference and at
least one other metabolic risk factor, Newtopia's method for habit
change produces significant beneficial change in several metabolic
risk factors and an average weight loss of 10 pounds or 4.3% of the
pre-program weight. Unpublished data from the three-year RCT
further indicate that the program's weight loss benefit persists
for at least three years. Such durable clinical benefits lead to an
annual cost savings of at least $1,464 per participant.iii
Leveraging this very same habit change platform, Newtopia's
GLP-1 Sustain combines genetic testing for risk factors and
key behaviors with individualized live coaching, curated content,
and remote monitoring from smart devices to help any GLP-1 user
identify, develop, and internalize constructive lifestyle habits
necessary to sustain weight loss, health, and well-being over time
– whether users remain on, or ultimately stop taking these
medications.
"We are very excited to bring our proven engagement and habit
change value-proposition to the GLP-1 juggernaut," says Newtopia
Founder and CEO Jeff Ruby. "We know
from experience that we can produce sustainable habit change in
this patient population – just as we have done for every other
population we serve."
GLP-1 Sustain will also produce significant annual
cost savings for Newtopia clients of ~$10,000+ per participant
(i.e. the average annual cost of GLP-1 medications of ~$12,000 replaced post-plateau, or if users cease
the medication, with the average annual value-based cost of
Newtopia of ~$750).
At less than 1/10th the cost of these drugs, GLP-1
Sustain offers a proven, scalable, and affordable pathway to
preserve the weight loss and other health benefits produced by
GLP-1 medications for millions of Americans.
"Newtopia's GLP-1 Sustain may be 'The Missing Piece' we
need to resolve a cost-benefit conundrum in one of the fastest
growing drug markets of all time," said Greg Steinberg, MD – cardiologist, former Head
of Clinical Innovation at Aetna, and former CEO of ActiveHealth
Management. "Payers and employers must balance the urgent need to
produce meaningful health outcomes in their populations with the
practical need to produce positive returns on their spend. If the
weight does not stay off, the expense of GLP-1s and related drugs
is hard to justify. But if Newtopia helps users sustain their
weight loss, especially when they cycle off the drug protocol,
payers, employers, and providers can begin to rationalize
prescribing and funding greater access to these medications."
About Newtopia
Newtopia is a personalized whole health platform helping people
create positive lifelong habits that prevent, slow, or reverse
chronic disease while reducing healthcare costs. The
platform leverages
genetic, social and behavioral insights
to create individualized prevention programs
with a focus on metabolic disease, diabetes, mental health
challenges, hypertension, weight management and musculoskeletal
disorders. With a person-centered approach that combines
virtual care, digital tools, connected devices and actionable data
science, Newtopia
delivers sustainable clinical and financial outcomes. Newtopia serves
some of the largest nationwide employers and health
plans and is currently listed in Canada on the Toronto
Stock Exchange (TSXV: NEWU) and is quoted in the US on
the OTCQB® Venture Market (OTCQB: NEWUF). To
learn more, visit newtopia.com, LinkedIn or X.
Forward Looking
Statements
This news release contains forward-looking information and
forward-looking statements, within the meaning of applicable
Canadian securities legislation, and forward looking statements,
within the meaning of applicable United
States securities legislation (collectively,
"forward-looking statements"), which reflects management's
expectations regarding Newtopia's future growth, results from
operations (including, without limitation, future production and
capital expenditures), performance (both operational and financial)
and business prospects and opportunities. Wherever possible, words
such as "predicts", "projects", "targets", "plans", "expects",
"does not expect", "budget", "scheduled", "estimates", "forecasts",
"anticipate" or "does not anticipate", "believe", "intend" and
similar expressions or statements that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved, or the negative or grammatical variation thereof or
other variations thereof, or comparable terminology have been used
to identify forward-looking statements. All statements other than
statements of historical fact may be forward- looking information.
Such statements reflect Newtopia's current views and intentions
with respect to future events, based on information available to
Newtopia, and are subject to certain risks, uncertainties, and
assumptions. Material factors or assumptions were applied in
providing forward-looking information. While forward-looking
statements are based on data, assumptions and analyses that
Newtopia believes are reasonable under the circumstances, whether
actual results, performance or developments will meet Newtopia's
expectations and predictions depends on a number of risks and
uncertainties that could cause the actual results, performance and
financial condition of Newtopia to differ materially from its
expectations. Forward-looking statements are not a guarantee and
are based on a number of estimates and assumptions management
believes to be relevant and reasonable, whether actual results,
performance or developments will meet Newtopia's expectations and
predictions depends on a number of risks and uncertainties that
could cause the actual results, performance and financial condition
of Newtopia to differ materially from its expectations. Certain of
the "risk factors" that could cause actual results to differ
materially from Newtopia's forward-looking statements in this press
release include, without limitation: the termination of contracts
by clients, risks related to COVID-19 including various
recommendations, orders and measures of governmental authorities to
try to limit the pandemic, including travel restrictions, border
closures, non-essential business closures, quarantines,
self-isolations, shelters- in-place and social distancing,
disruptions to markets, economic activity, financing, supply chains
and sales channels, and a deterioration of general economic
conditions including a possible national or global recession; and
other general economic, market and business conditions and factors,
including the risk factors discussed or referred to in Newtopia's
disclosure documents, filed with the securities regulatory
authorities in certain provinces of Canada and available at www.sedar.com
including Newtopia's final long form prospectus dated March 30, 2020.
Should any factor affect Newtopia's in an unexpected manner, or
should assumptions underlying the forward- looking information
prove incorrect, the actual results or events may differ materially
from the results or events predicted. Any such forward-looking
information is expressly qualified in its entirety by this
cautionary statement. Moreover, Newtopia does not assume
responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release, and Newtopia undertakes no obligation to publicly update
or revise any forward-looking information, other than as required
by applicable law.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
_______________________________________________________________________________________________________________________________________________________
|
i
|
The GLP-1 Agonist
Plateau No One's Talking AboutMedPage Today
|
ii
|
Newtopia BOB
Outcomes
|
iii
|
Steinberg et al, 2015
- https://journals.lww.com/joem/Fulltext/2015/12000/Reducing_Metabolic_Syndrome_Risk_Using_a.3.aspx
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/newtopia-launches-glp-1-sustain-program-to-affordably-preserve-and-extend-valuable-health-benefits-of-novel-weight-loss-drugs-302046277.html
SOURCE Newtopia Inc.